These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11294104)

  • 1. [Update of the study on survival with early hormonal therapy associated with radiotherapy (EORTC 22863 Study) in patients with advanced prostatic cancer. Interview with Michel Bolla].
    Bolla M
    Recenti Prog Med; 2001 Feb; 92(2):128-9. PubMed ID: 11294104
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hormonal therapy associated with radiotherapy of advanced carcinoma of the prostate. Comment on the study and interview with Michel Bolla].
    Valdagni R; Zelefsky MJ
    Recenti Prog Med; 2001 Feb; 92(2):130-2. PubMed ID: 11294105
    [No Abstract]   [Full Text] [Related]  

  • 3. RTOG study shows improved survival for prostate cancer patients given adjuvant goserelin.
    Oncology (Williston Park); 2005 Aug; 19(9):1142. PubMed ID: 16402596
    [No Abstract]   [Full Text] [Related]  

  • 4. Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy.
    Scalliet P
    Acta Urol Belg; 1996 May; 64(2):63-4. PubMed ID: 8701815
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of prostate cancer with goserelin and radiotherapy.
    Schoen SS
    N Engl J Med; 1997 Dec; 337(23):1693; author reply 1694. PubMed ID: 9411235
    [No Abstract]   [Full Text] [Related]  

  • 6. [Integrated (surgical and hormonal) treatment of advanced prostatic carcinoma. Comment on the study and the interview with Edward M. Messing].
    Prayer Galetti T
    Recenti Prog Med; 2001 Feb; 92(2):126-7. PubMed ID: 11294103
    [No Abstract]   [Full Text] [Related]  

  • 7. Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
    Pollack A; Horwitz EM
    Nat Clin Pract Oncol; 2005 Jan; 2(1):12-3. PubMed ID: 16264846
    [No Abstract]   [Full Text] [Related]  

  • 8. Treating prostate cancer: another step forward.
    Harv Mens Health Watch; 1998 May; 2(10):7. PubMed ID: 9577263
    [No Abstract]   [Full Text] [Related]  

  • 9. [Radiotherapy combined with hormonal therapy as treatment method in patients with prostate cancer: still more questions than answers].
    Milecki P
    Przegl Lek; 2005; 62(12):1455-9. PubMed ID: 16786772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of the LHRH analogue zoladex depot alone and in combination with cyproterone acetate in the treatment of advanced prostatic cancer.
    Di Silverio F; Serio M; Costantini A
    J Chemother; 1989 Jul; 1(4 Suppl):1231-4. PubMed ID: 16312846
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer.
    Kaisary AV
    Prostate Cancer Prostatic Dis; 2005; 8(2):140-51. PubMed ID: 15852051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer: risk categories and role of hormones and radiotherapy.
    Lukka H
    Can J Urol; 2002 Jun; 9 Suppl 1():26-9. PubMed ID: 12121592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Goserelin and locally advanced prostate cancer: new indication. Pros and cons.
    Prescrire Int; 2000 Jun; 9(47):75-6. PubMed ID: 11010743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical strategies for improving the radiotherapeutic management of prostate cancer.
    Chuba PJ; Forman JD; Ben-Josef E; Hart KH; Porter AT
    Anticancer Res; 1997; 17(3A):1449-54. PubMed ID: 9179182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of prostate cancer with goserelin and radiotherapy.
    Vicini FA; Kini VR; Martinez AA
    N Engl J Med; 1997 Dec; 337(23):1693-4. PubMed ID: 9411236
    [No Abstract]   [Full Text] [Related]  

  • 16. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
    Milecki P; Kwias Z; Martenka DJ
    Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer.
    Haliloglu A; Baltaci S; Yaman O
    J Urol; 2007 Jan; 177(1):128-30. PubMed ID: 17162022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Reevaluation of MAB therapy and progress of endocrine therapy].
    Klotz L; Payne H; Gillatt D; Keane T; Morris C; Akaza H; Hirao ; Akakura K; Fukagai T
    Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
    [No Abstract]   [Full Text] [Related]  

  • 19. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.
    Pilepich MV; Winter K; Lawton CA; Krisch RE; Wolkov HB; Movsas B; Hug EB; Asbell SO; Grignon D
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1285-90. PubMed ID: 15817329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer--the therapeutic challenge of locally advanced disease.
    Blasko JC; Lange PH
    N Engl J Med; 1997 Jul; 337(5):340-1. PubMed ID: 9233872
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.